Alport Syndrome Clinical Trial Pipeline Insights | DelveInsight

DelveInsight's, "Alport Syndrome Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Alport Syndrome pipeline landscape. It covers the Alport Syndrome pipeline drug profiles, including Alport Syndrome clinical trials and nonclinical stage products. It also covers the Alport Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Alport Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Alport Syndrome clinical trials, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Alport Syndrome Pipeline Report

• DelveInsight's Alport Syndrome pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Alport Syndrome treatment.
• The leading Alport Syndrome Companies include Eloxx Pharmaceuticals Inc, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics Inc, Reata Pharmaceuticals, and others.
• Promising Alport Syndrome Pipeline Therapies include Bardoxolone Methyl, RG012, and others.
• The Alport Syndrome Companies and academics are working to assess challenges and seek opportunities that could influence in Alport Syndrome R&D. The Alport Syndrome pipeline therapies under development are focused on novel approaches to treat/improve Alport Syndrome.

Request a sample and discover the recent breakthroughs and advances in Alport Syndrome treatment and get a snapshot of the Alport Syndrome Pipeline Outlook @ https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Alport Syndrome Overview

Alport syndrome, also known as hereditary nephritis is a genetic disorder arising from the mutations in the genes encoding alpha-3, alpha-4, and alpha-5 of type 4 collagen (COL4A3, COL4A4, COL4A5) or collagen 4 α345 network. The type 4 collagen alpha chains are primarily located in the kidneys, eyes, and cochlea. Alport syndrome is X-linked (XLAS) and can be transmitted in an autosomal recessive (ARAS) or autosomal dominant fashion (ADAS). In 1927, the syndrome of hereditary nephritis and deafness was described by a British physician, A. Cecil Alport. It was observed that hematuria was the most common symptom and males were affected more than females. In 1961, it was named Alport syndrome after having described in multiple family members. It is characterized by renal failure, bilateral sensorineural hearing loss, and eye abnormalities. Eventually, the patients present with proteinuria, hypertension, progressive loss of kidney function (gradual decline in GFR), and end-stage renal disease.

Alport Syndrome Emerging Drugs

• Bardoxolone: Reata Pharmaceuticals, Inc.

Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease ("ADPKD").

Alport Syndrome Therapeutics Assessment

There are approx. 8+ key companies which are developing the therapies for Alport Syndrome. The companies which have their Alport Syndrome drug candidates in the most advanced stage, i.e. Preregistration include, Reata Pharmaceuticals.

Alport Syndrome Report Assessment

• Alport Syndrome Pipeline Product Profiles
• Alport Syndrome Therapeutic Assessment
• Alport Syndrome Pipeline Assessment
• Inactive Alport Syndrome Drugs assessment
• Unmet Needs

Learn more about the novel and emerging Alport Syndrome therapies and Alport Syndrome Clinical Trials @ https://www.delveinsight.com/sample-request/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Alport Syndrome Pipeline Report

• Coverage- Global
• Alport Syndrome Companies include Eloxx Pharmaceuticals Inc, Chinook Therapeutic, River 3 Renal Corp., Travere Therapeutics Inc, Reata Pharmaceuticals, and others.
• Alport Syndrome Pipeline Therapies include Bardoxolone Methyl, RG012, and others
• Alport Syndrome Therapeutics Assessment: Phases, Molecule Type, Route of Administration

Table of Content

1. Introduction
2. Alport Syndrome Executive Summary
3. Alport Syndrome: Overview
4. Alport Syndrome Pipeline Therapeutics
5. Alport Syndrome Therapeutic Assessment
6. Alport Syndrome - DelveInsight's Analytical Perspective
7. Late Stage Products (Preregestration)
8. Bardoxolone methyl: Reata Pharmaceuticals, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ELX-02: Eloxx Pharmaceuticals, Inc.
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Atrasentan: Chinook Therapeutics
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Alport Syndrome Key Companies
24. Alport Syndrome Key Products
25. Alport Syndrome- Unmet Needs
26. Alport Syndrome- Market Drivers and Barriers
27. Alport Syndrome- Future Perspectives and Conclusion
28. Alport Syndrome Analyst Views
29. Alport Syndrome Key Companies
30. Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Alport Syndrome drugs?
• How many Alport Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alport Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Alport Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alport Syndrome and their status?
• What are the key designations that have been granted to the Alport Syndrome emerging drugs?

Dive deep into rich insights into new Alport Syndrome treatment drugs and Alport Syndrome Drug Treatment Guidelines, visit @ https://www.delveinsight.com/sample-request/alport-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09193216187
Address: 304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

This release was published on openPR.